EW vs. BSX, SYK, MDT, BDX, IDXX, DXCM, RMD, STE, PODD, and BAX
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), STERIS (STE), Insulet (PODD), and Baxter International (BAX). These companies are all part of the "health care equipment" industry.
Edwards Lifesciences vs.
Edwards Lifesciences (NYSE:EW) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking.
Edwards Lifesciences received 282 more outperform votes than Boston Scientific when rated by MarketBeat users. Likewise, 70.85% of users gave Edwards Lifesciences an outperform vote while only 69.82% of users gave Boston Scientific an outperform vote.
79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 1.3% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 0.5% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Boston Scientific had 2 more articles in the media than Edwards Lifesciences. MarketBeat recorded 44 mentions for Boston Scientific and 42 mentions for Edwards Lifesciences. Boston Scientific's average media sentiment score of 1.28 beat Edwards Lifesciences' score of 1.10 indicating that Boston Scientific is being referred to more favorably in the news media.
Edwards Lifesciences currently has a consensus price target of $79.95, suggesting a potential upside of 8.35%. Boston Scientific has a consensus price target of $107.39, suggesting a potential upside of 2.67%. Given Edwards Lifesciences' higher possible upside, equities research analysts plainly believe Edwards Lifesciences is more favorable than Boston Scientific.
Edwards Lifesciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
Edwards Lifesciences has higher earnings, but lower revenue than Boston Scientific. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Edwards Lifesciences has a net margin of 72.93% compared to Boston Scientific's net margin of 11.07%. Edwards Lifesciences' return on equity of 19.40% beat Boston Scientific's return on equity.
Summary
Edwards Lifesciences beats Boston Scientific on 10 of the 19 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edwards Lifesciences Competitors List
Related Companies and Tools
This page (NYSE:EW) was last updated on 2/21/2025 by MarketBeat.com Staff
